In late 2025, a woman in her fifties paid US$2,500 for a Prenuvo whole-body MRI scan at one of the company's clinics. She was healthy, ran three times a week, and had no symptoms of anything. A few months later, according to a civil suit filed in January 2026, she suffered a major stroke. The complaint alleges that the scan, which had been marketed as catching hundreds of conditions before symptoms appear, missed clear signs of what was about to happen [1]. The case is at an early stage and Prenuvo has not admitted liability. But it crystallises a question the rest of us have been able to avoid by not paying the bill: what, exactly, are these scans actually good for?
The whole-body MRI industry has gone from a curiosity to a cultural fixture in three years. Prenuvo, the Vancouver-headquartered company often treated as the category leader, says its scan captures 1.3 billion data points in under an hour with no radiation and no contrast dye, screening for "hundreds of conditions" across major organ systems [2]. It offers three membership tiers ranging from a roughly 45-minute "Core" scan to a 75-minute "Executive" package that adds brain, heart and body-composition analysis. Ezra, a New York-based competitor, sells a base 22-minute MRI for $999 covering 13 organs from head to pelvis, and upwards to a $3,999 full skeletal-and-neurological package [3]. Both companies market aggressively to a specific kind of buyer: the health-conscious, often already low-risk adult with disposable income and a belief that early detection is always better than later detection. Kim Kardashian, Bryan Johnson, Mark Hyman and Tim Ferriss have all publicly endorsed the scans [4][5]. Prenuvo has raised over $100 million in venture funding, including a $70 million round in late 2023 led by Felicis Ventures, and reported more than 100,000 members scanned at the time of that round [6].
The technology is real. The marketing is the part that outruns the science.
What a whole-body MRI scan actually does
A standard diagnostic MRI uses strong magnetic fields and radio waves to produce detailed images of soft tissue. A whole-body scan stitches together multiple sequences , typically brain, neck, chest, abdomen and pelvis , to give a radiologist something close to a full inventory of the body's major structures. Prenuvo's flagship scan uses 1.3 billion data points to produce roughly 1,300 cross-sectional images in under an hour, all without ionising radiation [2]. Ezra's 22-minute base scan covers head, neck, abdomen and pelvis, with optional add-ons for spine and skeletal assessment [3]. Neither company offers a true full-body scan in the literal sense: both exclude parts of the body. Prenuvo's whole-body scan is brain-to-pelvis, missing limbs. Ezra's base package excludes chest, lungs, heart, breasts, arms, legs and the entire gastrointestinal tract, including the colon [3]. That last exclusion matters, because colorectal cancer is one of the few cancers where screening has a clear, evidence-based mortality benefit.
The scans are not the same as the targeted screening tests that public health bodies actually recommend. Mammography, colonoscopy, low-dose CT for lung cancer in smokers, and HPV cervical screening all have randomised-trial data behind them showing they reduce deaths in specific populations. Whole-body MRI in asymptomatic adults has no such data. The American College of Radiology, the U.S. professional body for radiologists, does not endorse whole-body MRI screening in asymptomatic adults, citing the absence of evidence that it reduces morbidity or mortality and the documented risk of false positives and incidental findings [7]. A 2024 editorial in BMJ Evidence-Based Medicine reached the same conclusion: no high-quality evidence supports whole-body MRI screening in asymptomatic adults, and there are well-documented harms [8].
The incidentaloma problem
The central clinical objection to whole-body screening is not that the scans find nothing. It is that they find too much, and that what they find is often not the kind of thing that justifies acting on it.
A 2023 retrospective cohort study in eClinicalMedicine followed asymptomatic adults who underwent commercial whole-body MRI screening and found that a high proportion of scans surfaced at least one incidental finding requiring follow-up. Most were benign or of unclear clinical significance, but a meaningful subset triggered further imaging, biopsies or specialist referrals [9]. A 2023 narrative review in Insights into Imaging framed whole-body screening as a "double-edged sword": the technology is real, the evidence base is not yet there to recommend population-level screening, and any such program would need a robust protocol for managing the inevitable wave of incidentalomas, including clear follow-up criteria, radiologist expertise, and patient counselling [10]. A 2021 editorial in Radiology, the journal of the Radiological Society of North America, argued that without standardised reporting frameworks (the kind that exist for lung nodules under C-RADS) and clear downstream protocols, the harms of screening can outweigh the benefits [11].
The "incidentaloma" problem is structural, not a flaw of any one vendor. Modern imaging at high resolution surfaces tiny nodules, cysts and lesions in almost everyone's body. The clinical question is always the same: does this finding actually matter? In a 40-year-old with no symptoms, a 4mm thyroid nodule, a tiny renal cyst, or a small pulmonary nodule is much more likely to be a harmless feature of normal anatomy than an early cancer. But once it is on a report in front of a patient who paid $1,000 to $2,500 for the privilege of getting one, the path of least resistance is to scan it again in three months, then again, then to biopsy, then to surgery. A 2021 BMJ analysis on overdiagnosis put the conceptual point bluntly: detecting a subclinical abnormality does not guarantee that treating it improves outcomes, and may instead produce harm through biopsies, overtreatment and anxiety [12].
The asymmetry is real. A scan that catches one early pancreatic cancer in 5,000 customers is a powerful anecdote. A scan that triggers 200 biopsies of benign nodules across those same 5,000 customers is a quiet cost paid in anxiety, complications, and a small number of avoidable surgical procedures. The companies do not publish the second number. The peer-reviewed literature consistently suggests it is much larger than the first [9][10][11][12].
What the companies say, and what they don't
Prenuvo's homepage describes the scan as helping customers "see the full picture of your health" and frames the offering around early detection, longevity, and proactive screening [2]. Ezra's marketing is more direct: "Ezra has helped 6% of our members identify potential cancer," the company states, alongside a 22-minute scan covering 13 organs and a statistic from the American Cancer Society that "early cancer detection has an 80% survival rate, compared to less than 20% for late-stage cancer" [3].
Both claims are technically true and substantively misleading. The 6% figure is a real number but it is not a measure of lives saved; it is a measure of how often something flagged on a scan led to a downstream cancer diagnosis, with no denominator for false positives, no comparison group, and no follow-up data on outcomes. The 80%-vs-20% survival statistic is also real, but it is about the difference between stage I and stage IV cancer in general. It does not say anything about whether finding a stage I cancer via a $1,000 scan in an asymptomatic adult improves that person's outcomes compared to finding it the usual way, and it does not account for overdiagnosis of indolent lesions that would never have caused harm [12]. Both companies, in other words, are using real numbers to sell a real-sounding claim that the data does not actually support.
There is also a regulatory wrinkle worth flagging. Ezra received FDA 510(k) clearance in March 2023 for an AI-assisted prostate cancer detection tool that analyses MRI images [13]. That is a real clearance, but it is for prostate only, not for a general "whole-body cancer screening" indication. The American College of Radiology has noted the lack of FDA clearance for whole-body MRI as a screening device for cancer in asymptomatic populations [7]. The two facts are sometimes conflated in marketing copy.
Who, if anyone, should consider one
None of this means whole-body MRI is useless. The technology is genuinely good at certain things: imaging soft tissue without radiation, picking up structural abnormalities in the brain and abdomen, and finding things like aneurysms, certain kidney tumours, and some liver lesions that would otherwise be silent until symptomatic. People with a strong family history of certain cancers, known genetic syndromes (Li-Fraumeni, Lynch), or specific clinical concerns that have already been discussed with a physician may genuinely benefit from a more extensive imaging work-up than the standard screening battery offers.
What whole-body MRI is not, in 2026, is a routine wellness purchase for healthy adults. The American College of Radiology position is the consensus view of mainstream radiology: the evidence for mortality benefit in asymptomatic adults is not there, the harms of incidental findings are documented, and targeted screening based on age, sex and risk factors remains the standard of care [7]. The BMJ EBM 2024 editorial calls whole-body screening a "preference-sensitive" choice, which is academic shorthand for: it is your money, but you are paying for a service the evidence does not endorse [8].
The honest framing in mid-2026 is somewhere between the marketing and the dismissal. Prenuvo and Ezra are real companies doing real imaging, and individual customers have benefited. They are also selling a feeling more than a diagnosis, and the structural incentive to find things is in unavoidable tension with the medical principle of not looking for trouble you do not have a plan to deal with. The January 2026 lawsuit will be the first major legal test of the marketing language [1]; it will not be the last.
If you are weighing one of these scans for yourself, the most useful question is not "could it catch something early?" It is "what will I do with what it finds, and have I discussed this with my actual doctor first?" For most healthy adults, the answer to that second question is enough to put the $1,000 to $2,500 toward a colonoscopy, a dermatologist visit, and a pair of running shoes. The evidence is much clearer on those.